Company intelligence / Profile preview

Greywolf Capital Management

Oxford, Oxfordshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Grey Wolf Therapeutics is advancing a unique therapeutic strategy that leverages the inhibition of ERAP1 and ERAP2 to modulate antigen presentation and elicit targeted immune responses. Initial data on GRWD5769, a potent ERAP1 inhibitor, is expected to be presented at ASCO 2024.

Therapeutic areas: OncologyImmunology
Modalities: Small molecules
Industry: Investors

Beyond the preview

Go deeper on Greywolf Capital Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greywolf Capital Management.

Explore the full profile